Study drug before surgery for early-stage triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether giving a targeted drug before surgery can help shrink early-stage triple-negative breast cancer tumors. It may be an option for people who have not yet had any treatment for their breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have early-stage triple-negative breast cancer (tumors that do not have receptors for estrogen, progesterone, or HER2).
- You have not had any prior chemotherapy, radiation, or other treatment for this breast cancer.
- You are generally healthy and able to perform daily activities (ECOG 0-1).
- You have a tumor that can be measured on imaging scans and you are willing to provide a tissue sample.
- Your heart, liver, kidney, and blood counts are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.